Childhood Height Growth Rate Association With the Risk of Islet Autoimmunity and Development of Type 1 Diabetes
(2022) In Journal of Clinical Endocrinology and Metabolism 107(6). p.1520-1528- Abstract
Context: Rapid growth has been suggested to promote islet autoimmunity and progression to type 1 diabetes (T1D). Childhood growth has not been analyzed separately from the infant growth period in most previous studies, but it may have distinct features due to differences between the stages of development. Objective: We aimed to analyze the association of childhood growth with development of islet autoimmunity and progression to T1D diagnosis in children 1 to 8 years of age. Methods: Longitudinal data of childhood growth and development of islet autoimmunity and T1D were analyzed in a prospective cohort study including 10 145 children from Finland, Germany, Sweden, and the United States, 1-8 years of age with at least 3 height and weight... (More)
Context: Rapid growth has been suggested to promote islet autoimmunity and progression to type 1 diabetes (T1D). Childhood growth has not been analyzed separately from the infant growth period in most previous studies, but it may have distinct features due to differences between the stages of development. Objective: We aimed to analyze the association of childhood growth with development of islet autoimmunity and progression to T1D diagnosis in children 1 to 8 years of age. Methods: Longitudinal data of childhood growth and development of islet autoimmunity and T1D were analyzed in a prospective cohort study including 10 145 children from Finland, Germany, Sweden, and the United States, 1-8 years of age with at least 3 height and weight measurements and at least 1 measurement of islet autoantibodies. The primary outcome was the appearance of islet autoimmunity and progression from islet autoimmunity to T1D. Results: Rapid increase in height (cm/year) was associated with increased risk of seroconversion to glutamic acid decarboxylase autoantibody, insulin autoantibody, or insulinoma-like antigen-2 autoantibody (hazard ratio [HR] = 1.26 [95% CI = 1.05, 1.51] for 1-3 years of age and HR = 1.48 [95% CI = 1.28, 1.73] for >3 years of age). Furthermore, height rate was positively associated with development of T1D (HR = 1.80 [95% CI = 1.15, 2.81]) in the analyses from seroconversion with insulin autoantibody to diabetes. Conclusion: Rapid height growth rate in childhood is associated with increased risk of islet autoimmunity and progression to T1D. Further work is needed to investigate the biological mechanism that may explain this association.
(Less)
- author
- Li, Zhiguo
; Veijola, Riitta
; Koski, Eileen
; Anand, Vibha
; Martin, Frank
; Waugh, Kathleen
; Hyöty, Heikki
; Winkler, Christiane
; Killian, Michael B.
; Lundgren, Markus
LU
; Ng, Kenney
; Maziarz, Marlena
LU
and Toppari, Jorma
(Less) - organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- autoantibodies, child growth, prospective cohort, type 1 diabetes
- in
- Journal of Clinical Endocrinology and Metabolism
- volume
- 107
- issue
- 6
- pages
- 1520 - 1528
- publisher
- Oxford University Press
- external identifiers
-
- pmid:35244713
- scopus:85130766691
- ISSN
- 0021-972X
- DOI
- 10.1210/clinem/dgac121
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2022 The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.
- id
- 54ce9f1c-9a47-4f27-b48e-b792873b33b4
- date added to LUP
- 2022-08-16 16:25:15
- date last changed
- 2025-02-21 19:44:12
@article{54ce9f1c-9a47-4f27-b48e-b792873b33b4,
abstract = {{<p>Context: Rapid growth has been suggested to promote islet autoimmunity and progression to type 1 diabetes (T1D). Childhood growth has not been analyzed separately from the infant growth period in most previous studies, but it may have distinct features due to differences between the stages of development. Objective: We aimed to analyze the association of childhood growth with development of islet autoimmunity and progression to T1D diagnosis in children 1 to 8 years of age. Methods: Longitudinal data of childhood growth and development of islet autoimmunity and T1D were analyzed in a prospective cohort study including 10 145 children from Finland, Germany, Sweden, and the United States, 1-8 years of age with at least 3 height and weight measurements and at least 1 measurement of islet autoantibodies. The primary outcome was the appearance of islet autoimmunity and progression from islet autoimmunity to T1D. Results: Rapid increase in height (cm/year) was associated with increased risk of seroconversion to glutamic acid decarboxylase autoantibody, insulin autoantibody, or insulinoma-like antigen-2 autoantibody (hazard ratio [HR] = 1.26 [95% CI = 1.05, 1.51] for 1-3 years of age and HR = 1.48 [95% CI = 1.28, 1.73] for >3 years of age). Furthermore, height rate was positively associated with development of T1D (HR = 1.80 [95% CI = 1.15, 2.81]) in the analyses from seroconversion with insulin autoantibody to diabetes. Conclusion: Rapid height growth rate in childhood is associated with increased risk of islet autoimmunity and progression to T1D. Further work is needed to investigate the biological mechanism that may explain this association. </p>}},
author = {{Li, Zhiguo and Veijola, Riitta and Koski, Eileen and Anand, Vibha and Martin, Frank and Waugh, Kathleen and Hyöty, Heikki and Winkler, Christiane and Killian, Michael B. and Lundgren, Markus and Ng, Kenney and Maziarz, Marlena and Toppari, Jorma}},
issn = {{0021-972X}},
keywords = {{autoantibodies; child growth; prospective cohort; type 1 diabetes}},
language = {{eng}},
number = {{6}},
pages = {{1520--1528}},
publisher = {{Oxford University Press}},
series = {{Journal of Clinical Endocrinology and Metabolism}},
title = {{Childhood Height Growth Rate Association With the Risk of Islet Autoimmunity and Development of Type 1 Diabetes}},
url = {{http://dx.doi.org/10.1210/clinem/dgac121}},
doi = {{10.1210/clinem/dgac121}},
volume = {{107}},
year = {{2022}},
}